Comparative Pharmacology
Head-to-head clinical analysis: FREAMINE 8 5 versus FREAMINE III 8 5.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FREAMINE 8 5 versus FREAMINE III 8 5.
FREAMINE 8.5% vs FREAMINE III 8.5%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
FREAMINE 8.5% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintenance of nitrogen balance, and tissue repair in patients unable to tolerate oral or enteral nutrition.
FREAMINE III 8.5% is a crystalline amino acid solution that provides essential and non-essential amino acids for protein synthesis, nitrogen balance maintenance, and tissue repair. It acts as a substrate for protein anabolism in patients unable to tolerate adequate oral or enteral intake.
1 to 2 g/kg/day intravenously, typical adult dose 70-140 g/day (800-1650 mL of 8.5% solution), infused at a rate not exceeding 0.1 g/kg/hour
Intravenous infusion; typical adult dose is 0.8-1.5 g amino acids/kg/day (equivalent to 9.4-17.6 mL/kg/day of Freamine III 8.5%). Initiate at lower end and titrate to metabolic needs. Administer via central or peripheral line with dextrose and electrolytes as part of parenteral nutrition.
None Documented
None Documented
The terminal elimination half-life of infused amino acids is not conventionally defined as it depends on metabolic utilization. For most amino acids, plasma clearance is rapid (minutes to hours) with a pseudo-half-life of approximately 15-30 minutes for the initial distribution phase. Clinical context: half-life is irrelevant since amino acids are continuously metabolized and incorporated into proteins.
Terminal elimination half-life of infused amino acids is approximately 15-30 minutes for most, but albumin synthesis half-life is 20-22 days; clinical context: continuous infusion needed for nitrogen balance.
Amino acids from FREAMINE 8.5% are primarily metabolized via deamination and transamination pathways, with nitrogen waste excreted renally as urea (approx 80-90% of administered nitrogen). A small fraction is excreted via feces as unabsorbed amino acids (less than 5%). Biliary excretion is negligible.
Renal: 90-95% of infused amino acids are reabsorbed; excess nitrogen excreted as urea (80-90% of nitrogen load) and ammonia (<10%). Biliary/fecal: negligible (<5%).
Category C
Category C
Parenteral nutrition amino acid
Parenteral nutrition amino acid